

PRESSRELEASE

Stockholm, February 21, 2013



Sobi's additional issuance of SEK 200 million under current bond loan fully subscribed

As previously communicated, the Board of Directors of Swedish Orphan Biovitrum AB (Sobi) has decided to issue additional amounts the current bond loan with a loan frame of SEK 1 billion. The issuance of SEK 200 million in nominal amount is now fully subscribed.

Nordea Bank is acting as financial advisor to Sobi and Sole Bookrunner in conjunction with the issuance.

For further information, please contact:

Investor Relations: Jörgen Winroth

Phone: +46-(0)8-697 20 00

Email: jorgen.winroth@sobi.com

About Swedish Orphan Biovitrum AB (Sobi)

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

The above information has been made public in accordance with Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was released for public distribution on 21 February 2013 at 13.40 CET.